🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesDo the heart benefits go away if I stop taking it?

Do the heart benefits go away if I stop taking it?

SaraMom3 Wed, May 6, 2026 at 5:46 AM 7 replies 523 viewsPage 1 of 2
SaraMom3
Member
456
2,345
Aug 2024
Ohio
May 6, 2026 at 5:46 AM#1

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

What would genuinely help is knowing how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I have searched first, so if this is covered somewhere point me at it and I will read it.

35 5BethLabQueen, ChrisMacros, KetoKyle and 32 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 6, 2026 at 7:07 AM#2
SaraMom3 said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
34 4anna.melb_AU, mark_tokyo, hans_munich and 31 others
Reply Quote Save Share Report
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
May 6, 2026 at 8:28 AM#3
Dr.RaviCardio said:
Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
33 3Dr.SleepRoch, laura_annarbor, JenMemphis and 30 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
May 6, 2026 at 9:49 AM#4
SaraMom3 said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Same experience, arrived at from the opposite direction. Nothing to add that would improve it.

32 2DoseLogDan, SleepFixSam, PurityPaulOR and 29 others
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
May 6, 2026 at 5:38 PM#5

Adding the clinical framing, because it changes how the question reads.

6 month update on cardiovascular risk: down 37 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Last edited: May 6, 2026 at 11:38 PM
31 1kevin_tulsa, Dr.PainCLE, mike_mealprep and 28 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register